Zentrum fuer klinische Studien Suedbrandenburg GmbH — Clinical Trial Site

20 Registered trials

5 Currently recruiting

Organisation

Zentrum fuer klinische Studien Suedbrandenburg GmbH

Location

Elsterwerda, Germany

Identifier

ORG-100044761

Address

Lange Strasse 13, 04910, Germany

Departments

-
cardiology,diabetology
General Medicine / Internal Medicine
Klinische Studien
N/A
NA
Not applicable
Zentrum für Klinische Studien Südbrandenburg GmbH - Hagenow, Elsterwerda

Clinical trials at this site (20)

Search interface

OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
AMAZE 8: A research study investigating how well the medicine NNC0487-0111 compared to semaglutide helps people with excess body weight and … Recruiting

2024-520446-31-00 Participants with overweight or obesity, and type 2 dia 5 2026-05-27
AMAZE 1: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight lose weight Recruiting

2024-520440-42-00 Obesity 5 2026-05-07
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT… Ended

2024-515523-11-00 Chronic Weight Management 5 2025-06-09
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA… Ended

2024-515524-36-00 Chronic Weight Management 5 2025-05-30
ATHENA: A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation Ended

2023-506988-34-00 Heart failure with mildly reduced or preserved ejection 5 2024-03-27
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A research study to see how well CagriSema helps people with excess body weight lose weight Ended

2023-506929-11-00 Overweight and obesity 5 2022-10-17
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec… Ended

2023-508736-62-00 Heart failure (HF) with reduced ejection fraction (HFrE 4 2024-08-08
A Phase 2 Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejecti… Ended

2023-508737-13-00 chronic heart failure 4 2024-08-08
A clinical research study to learn if baxdrostat works at reducing ambulatory blood pressure and is safe for people with high blood pressure… Ended

2023-507640-36-00 Resistant hypertension (rHTN) defined as blood pressure 5 2024-04-29
A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended

2023-505499-32-00 Uncontrolled hypertension (uTHN) defined as blood press 5 2024-03-08
REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight… Ended

2022-502678-18-00 Type 2 diabetes 5 2023-11-07
A research study to see how well CagriSema helps people with type 2 diabetes and excess body weight lose weight Ended

2023-506931-13-00 Overweight and obesity and type 2 diabetes 5 2023-01-30